1. "2020"
Formats
  1. Journal Article (2337)
  2. Meeting Abstract (1901)
  3. Review (494)
  4. Editorial (342)
  5. Correspondence (121)
  6. Guidelines (114)
  7. Book Section (99)
  8. Research Letter (95)
  9. Miscellaneous (61)
  10. Conference Paper (33)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2560)
  2. Solid Tumor Oncology Division (1535)
  3. GSK Faculty (1257)
  4. Sloan Kettering Institute Postdocs (1240)
  5. Hematologic Malignancies, Division of (936)
  6. Survivorship Research (930)

More Groups

People
  1. Jorge Reis-Filho (93)
  2. Miguel-Angel Perales (93)
  3. Sergio Giralt (91)
  4. Alexander Drilon (81)
  5. Britta Weigelt (76)
  6. Nadeem Abu-Rustum (71)

More People

Years
  1. 2020 (5599)
Publications
  1. Journal of Clinical Oncology (500)
  2. Blood (212)
  3. Cancer Research (185)
  4. Annals of Oncology (152)
  5. International Journal of Radiation Oncology, Biology, Physics (129)
  6. Laboratory Investigation (116)

More Publications

Publishers
  1. Elsevier Inc. (714)
  2. American Society of Clinical Oncology (548)
  3. Nature Publishing Group (385)
  4. American Association for Cancer Research (357)
  5. Oxford University Press (356)
  6. Springer (342)

More Publishers

Results (5599)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nasal vestibulitis: An MNCCTN natural history trial - Nasal vestibulitis symptoms associated with paclitaxel, docetaxel, and other chemotherapy agents
    Meeting Abstract

    Cathcart-Rake, E. J.; Zahrieh, D.; Smith, D. S.; Young, S.; Wolfe, E. G.; O'Connor, A.; Thome, S.; Lacouture, M. E.; Register, T.; Piens, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Powles, T.; Scheffold, C.; Wang, F.; Motzer, R. J.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma
    Meeting Abstract

    Cercek, A.; Stadler, Z. K.; Cohen, J. L.; Weiss, J. A.; Lamendola-Essel, M. F.; Krishnan, A.; Yaeger, R.; Segal, N. H.; Connell, L. C.; El Dika, I. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT)
    Meeting Abstract

    Campbell, M. T.; Zhang, T.; Chin, L.; Warner, A. B.; Mathew, M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE)
    Meeting Abstract

    Chi, K. N.; Rathkopf, D. E.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Ricci, D. S.; Simon, J. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Buxton, M. B.; Alexander, B. M.; Berry, D. A.; Cavenee, W. K.; Colman, H.; De Groot, J. F.; Ellingson, B. M.; Gordon, G. B.; Khasraw, M.; Lassman, A. B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Ben, Tran; Horvath, L.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Autio, K. A.; Rottey, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914)
    Meeting Abstract

    Bex, A.; Russo, P.; Tomita, Y.; Grunwald, V.; Ramirez, L. M.; McHenry, B. M.; Motzer, R. J.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101)
    Meeting Abstract

    Blumenschein, G. R. Jr; Davar, D.; Gutierrez, R.; Segal, N. H.; Johnson, M. L.; Dar, M. M.; Marshall, S.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Patient journey and quality of life (QOL) among diffuse-type TGCT in the US
    Meeting Abstract

    Bernthal, N. M.; Spierenburg, G.; van de Sande, M.; Healey, J. H.; Stacchiotti, S.; Bauer, S.; Gelderblom, H.; Staals, E.; Bastida, J. L.; Fronk, E. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save